- Mekonos, a San Francisco, CA-based biotech company launching a system-on-a-chip (SoC) for targeted ex vivo gene engineering, completed a $4.6m financing round
- The round was led by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures
- The company will also use the new capital to accelerate the SoC platform for its current and new commercial partnerships
- Led by Anil Narasimha, Ph.D., Co-Founder and CEO, Mekonos is a biotech company advancing a gene engineering platform SoC platform, with IP from Stanford University
- The platform also helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space
- Mekonos recently completed pilots with key top pharmaceutical companies and research institutes that demonstrated high efficacy of modified gene expression and cell viability
